| Biotechnology Industry | Healthcare Sector | Mr. Jie Wu M.B.A. CEO | XSHE Exchange | CNE100005K44 ISIN |
| CN Country | 2,208 Employees | 8 Jul 2025 Last Dividend | 29 Jun 2023 Last Split | - IPO Date |
R&G PharmaStudies Co., Ltd. is a company based in Beijing, China, specializing in providing comprehensive clinical research outsourcing services. Catering to pharmaceutical and medical device companies as well as scientific research institutions within China, R&G PharmaStudies offers a wide range of services aimed at enhancing the efficiency and effectiveness of clinical trials. Since its establishment in 2008, the company has been dedicated to supporting the development and research efforts of its clients through specialized services covering various aspects of clinical trials, including consultation, operation, data management, statistical analysis, and site management.
Expert advice on clinical trial design, regulatory requirements, and strategy to ensure effective and compliant study implementation.
Comprehensive management services that encompass planning, execution, and monitoring of clinical trials to achieve study goals efficiently.
Management of clinical trial data through systematic processing, along with advanced statistical analysis to ensure data integrity and insightful analysis.
Provision of technological support and innovative solutions for various challenges encountered during clinical trial operations.
Application of biostatistical methods to support scientific research, ensuring rigorous quantification and analysis of research data.
Offering services related to the data monitoring committee of clinical trials including participation in the committee or performing relevant statistical analysis for the committee.
Specialized pharmacological support throughout the drug development process, focusing on the pharmacokinetics and pharmacodynamics of compounds.
Advanced testing services to analyze and detect biological samples collected during clinical trials for determining the concentration of the original drug and/or its metabolites.
Management and oversight of clinical trial sites to ensure compliance, efficiency, and high standards of data collection and participant care.